Clinical characteristics of ACPA+ individuals (n=103)
| Characteristic | Result |
|---|---|
| Progressed (ever): % (n) | 46.6% (48) |
| Duration of follow-up (months) median (range) | 18.4 (0.1 to 79.6) |
| Age (years) mean (SD; range) | 52.6 (11.7; 27 to 79) |
| Female: % (n) | 71.8% (74) |
| SE positive %(n)* | 73.5% (72) |
| High positive ACPA and/or RF†: % (n) | 85.4% (88) |
| Smoker: % (n) | |
| Non-smoker | 30.1 (31) |
| Ex-smoker | 41.7 (43) |
| Current smoker | 28.2 (29) |
| EMS≥30 mins: % (n) | 34.0% (35) |
| Small joint symptoms: % (n) | 43.7% (45) |
*Available in 98/103 patients.
†Determined as >3×upper limit of normal.
ACPA, anticitrullinated protein antibody; EMS, early morning stiffness; RF, rheumatoid factor; SE, shared epitope.